Joel M. Topf, MD, FACP
Articles by Joel M. Topf, MD, FACP
Guru Reddy discussed three posters presented by Unicycive Therapeutics at ASN Kidney Week 2024, on UNI-494 and OLC.
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
Melissa Little discussed kidney regeneration and her stem cell research with Joel Topf of Nephrology Times.
Mohamad Hussain spoke with us about a phase 3 trial of the acellular tissue engineered vessel in AV access for hemodialysis.
After their poster tour at ASN Kidney Week 2024, Roger Rodby and Edgar Lerma shared a few highlights with Joel Topf.
Katherine Tuttle spoke with Joel Topf about FLOW trial results presented at ASN Kidney Week 2024.
Hiddo Heerspink discussed his Kidney Week presentations on SC0062 for IgAN and semaglutide in obesity with nondiabetic CKD.
Jonathan Barratt discussed his research on the anti-APRIL antibody sibeprenlimab in the treatment of IgA nephropathy.
Abdul Abdellatif discussed findings from the PROTECT study examining pegloticase for kidney transplant patients with gout.
Members of the Nephrology Times editorial board shared the nephrology research and news they’ve found most notable this ...
Cesia Portillo discussed her poster on creating a roadmap for APOL1-mediated kidney disease (AMKD).
Suzanne Watnick shared thoughts on the Shaul G. Massry lectureship, COVID-19, kidney transplantation, and policy issues.
A. Ersin Yassa and Yasemin Balin were the winners of the inaugural Neph Madness tournament.
Martin Pollak reflected on winning the David M. Hume Memorial Award and on breakthroughs in glomerular diseases.
Sylvia Rosas shared highlights from her term as president of the National Kidney Foundation.
Areef Ishani spoke about his abstract on renal outcomes with chlorthalidone versus hydrochlorothiazide for hypertension.
Editorial board member Joel Topf reflects on the NKF Spring Clinical Meetings and the value of #NephTwitter.
Dr. Robert Montgomery spoke about advances in xenotransplantation, including the pig kidney transplant he recently performed.
Dr. Dana Rizk discussed her APPLAUSE-IgAN study findings on iptacopan versus placebo for IgA nephropathy.
Vlado Perkovic has not presented the results of the FLOW trial, but the surprise is gone. We know what he is going to say.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.